NRx Pharmaceuticals, Inc. announced that the US Food and Drug Administration (FDA) has declined to issue an Emergency Use Authorization (EUA) for ZYESAMI® (aviptadil) for a sub-group of patients that in addition to ZYESAMI®, also received Remdesivir and continued to progress. NRx Pharmaceuticals had submitted this last EUA application using data from a post-hoc subgroup analysis.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.1 USD | +1.94% | -40.68% | -54.35% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-54.35% | 21.88M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- BRPA Stock
- News NRx Pharmaceuticals, Inc.
- Nrx Pharmaceuticals, Inc. Announces FDA Declines Emergency Use Authorization for Zyesami® for Subgroup of Patients with Critical Covid-19 At Immediate Risk of Death from Respiratory Failure Despite Treatment with Approved Therapy, Including Remdesivir